Duopharma Biotech Berhad (KLSE:DPHARMA) - Aandelenkoers, Nieuws & Analyse

DPHARMA Overzicht aandelen

DPHARMA fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	4/6
Prestaties in het verleden	2/6
Financiële gezondheid	4/6
Dividenden	3/6

Beloningen

Verhandeld tegen 13.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 23.04% per jaar groeien

Risicoanalyse

Onstabiel dividend track record

Duopharma Biotech Berhad Concurrenten

Apex Healthcare Berhad

KLSE:AHEALTH

RM 1.9b

Kotra Industries Berhad

KLSE:KOTRA

RM 642.2m

Y.S.P. Southeast Asia Holding Berhad

KLSE:YSPSAH

RM 322.0m

Rhone Ma Holdings Berhad

KLSE:RHONEMA

RM 149.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Duopharma Biotech Berhad
Historische aandelenkoersen
Huidige aandelenkoers	RM 1.24
52 Week Hoogtepunt	RM 1.45
52 Week Laag	RM 1.10
Bèta	0.68
11 maand verandering	-5.34%
3 maanden verandering	0%
1 Jaar Verandering	1.64%
33 jaar verandering	-27.49%
5 jaar verandering	18.94%
Verandering sinds IPO	207.51%

Recent nieuws en updates

Recent updates

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12

Rendement voor aandeelhouders

	DPHARMA	MY Pharmaceuticals	MY Markt
7D	1.6%	0.2%	0.09%
1Y	1.6%	-0.4%	9.5%

Rendement versus industrie: DPHARMA overtrof de MY Pharmaceuticals industrie, die het afgelopen jaar een rendement -0.4 % opleverde.

Rendement versus markt: DPHARMA presteerde slechter dan MY Market, dat het afgelopen jaar een rendement van 9.5 % opleverde.

Prijsvolatiliteit

Is DPHARMA's price volatile compared to industry and market?
DPHARMA volatility
DPHARMA Average Weekly Movement	3.7%
Pharmaceuticals Industry Average Movement	3.6%
Market Average Movement	5.1%
10% most volatile stocks in MY Market	10.4%
10% least volatile stocks in MY Market	2.5%

Stabiele aandelenkoers: DPHARMA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van DPHARMA is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1978	1,650	Leonard bin Abdul Shatar	duopharmabiotech.com

Duopharma Biotech Berhad, een investeringsholding, onderzoekt, ontwikkelt, produceert, distribueert en importeert farmaceutische producten en medicijnen in Maleisië en internationaal. Het bedrijf biedt gezondheidsproducten voor de consument, waaronder vitamines en supplementen, pijnstillers, oogverzorging, maagzuurremmers en huidverzorgingsproducten; en generieke geneesmiddelen voor verschillende therapeutische klassen, zoals hart- en vaatziekten, dermatologie, hormonen, ademhaling, zintuigen en zenuwstelsel, spier- en skeletstelsel, anti-infectiva en andere. Het bedrijf levert ook farmaceutische specialiteiten voor specifieke aandoeningen, biosimilaire producten en medische hulpmiddelen en verbruiksgoederen aan patiënten met aandoeningen zoals diabetes, kanker, hart- en vaatziekten, nierziekten en andere.

Duopharma Biotech Berhad Samenvatting

Hoe verhouden de winst en inkomsten van Duopharma Biotech Berhad zich tot de beurswaarde?
DPHARMA fundamentele statistieken
Marktkapitalisatie	RM 1.19b
Inkomsten(TTM)	RM 56.06m
Inkomsten(TTM)	RM 787.53m

21.3x

Koers/Winstverhouding

1.5x

P/S-verhouding

Is DPHARMA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DPHARMA resultatenrekening (TTM)
Inkomsten	RM 787.53m
Kosten van inkomsten	RM 506.08m
Brutowinst	RM 281.44m
Overige uitgaven	RM 225.38m
Inkomsten	RM 56.06m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.058
Brutomarge	35.74%
Nettowinstmarge	7.12%
Schuld/Eigen Vermogen Verhouding	75.4%

Hoe presteerde DPHARMA op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.3%

Huidig dividendrendement

48%

Uitbetalingsratio

DPHARMA Overzicht aandelen

Beloningen

Risicoanalyse

Duopharma Biotech Berhad Concurrenten

KLSE:AHEALTH

RM 1.9b

KLSE:KOTRA

RM 642.2m

KLSE:YSPSAH

RM 322.0m

KLSE:RHONEMA

RM 149.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: EPS: RM0.016 (vs RM0.009 in 3Q 2023)

Second quarter 2024 earnings released: EPS: RM0.017 (vs RM0.013 in 2Q 2023)

Duopharma Biotech Berhad Announces Retirement of Tan Sri, Datin Paduka Siti Sa'diah Binti Sh Bakir as Non-Independent and Non-Executive Chairman

New minor risk - Profit margin trend

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Duopharma Biotech Berhad, Annual General Meeting, Jun 06, 2024

Recent updates

Third quarter 2024 earnings released: EPS: RM0.016 (vs RM0.009 in 3Q 2023)

Second quarter 2024 earnings released: EPS: RM0.017 (vs RM0.013 in 2Q 2023)

Duopharma Biotech Berhad Announces Retirement of Tan Sri, Datin Paduka Siti Sa'diah Binti Sh Bakir as Non-Independent and Non-Executive Chairman

New minor risk - Profit margin trend

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Duopharma Biotech Berhad, Annual General Meeting, Jun 06, 2024

Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director

Consensus EPS estimates fall by 11%

Upcoming dividend of RM0.018 per share

Full year 2023 earnings released: EPS: RM0.055 (vs RM0.074 in FY 2022)

Now 20% undervalued

Third quarter 2023 earnings released: EPS: RM0.009 (vs RM0.017 in 3Q 2022)

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Price target decreased by 8.3% to RM1.63

Second quarter 2023 earnings released: EPS: RM0.013 (vs RM0.017 in 2Q 2022)

Duopharma Biotech Berhad Declares Interim Dividend for the 30 June 2023, Payable on 22 September 2023

Duopharma Biotech Berhad Appoints ENCIK MUHAMMAD SHUKRI BIN ISMAIL as Non Independent and Non Executive Alternate Director

Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman, Member of Nomination and Remuneration Committee as Independent and Non-Executive Chairman of Nomination and Remuneration Committee, Date of Change 1 June 2023

Duopharma Biotech Berhad Announces Retirement of Dato' Mohamad Kamarudin Bin Hassan as Independent and Non-Executive Member of Risk Committee

Full year 2022 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Upcoming dividend of RM0.018 per share at 1.5% yield

Full year 2022 earnings released: EPS: RM0.074 (vs RM0.071 in FY 2021)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target increased to RM1.81

Insufficient new directors

Third quarter 2022 earnings released: EPS: RM0.017 (vs RM0.018 in 3Q 2021)

Insufficient new directors

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Insufficient new directors

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Second quarter 2022 earnings released: EPS: RM0.017 (vs RM0.016 in 2Q 2021)

Duopharma Biotech Berhad Announces an Interim Dividend, Payable on 14 September 2022

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad, Annual General Meeting, Jun 21, 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of RM0.018 per share

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Full year 2021 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Declares Second Interim Dividend in Respect of the Financial Year Ended 31 December 2021

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Price target decreased to RM1.97

Third quarter 2021 earnings released: EPS RM0.018 (vs RM0.015 in 3Q 2020)

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Second quarter 2021 earnings released: EPS RM0.022 (vs RM0.022 in 2Q 2020)

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Upcoming dividend of RM0.06 per share

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Price target decreased to RM3.10

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment deteriorated over the past week